A review of structural modification and biological activities of oleanolic acid

Abstract

Oleanolic acid (OA), a pentacyclic triterpenoid, exhibits a broad spectrum of biological activities, including antitumor, antiviral, antibacterial, anti-inflammatory, hepatoprotective, hypoglycemic, and hypolipidemic effects. Since its initial isolation and identification, numerous studies have reported on the structural modifications and pharmacological activities of OA and its derivatives. Despite this, there has been a dearth of comprehensive reviews in the past two decades, leading to challenges in subsequent research on OA. Based on the main biological activities of OA, this paper comprehensively summarized the modification strategies and structure-activity relationships (SARs) of OA and its derivatives to provide valuable reference for future investigations into OA.

Keywords

Oleanolic acid / Derivatives / Pentacyclic triterpenoid / Structural modification / Biological activities

References

[1] Leal AS, Wang R, Salvador JAR, et al. Synthesis of novel heterocyclic oleanolic acid deriva-tives with improved antiproliferative activity in solid tumor cells[J]. Org Biomol Chem, 2013, 11(10): 1726-1738.

[2] Mengoni F, Lichtner M, Battinelli L, et al. In vitro anti-HIV activity of oleanolic acid on infected human mononuclear 893 cells[J]. Planta Med, 2002, 68(2): 111-114.

[3] Fontanay S, Grare M, Mayer J, et al. Ursolic, oleanolic and betulinic acids: antibacterial spectra and selectivity indexes[J]. J Ethnopharmacol, 2008, 120(2): 272-276.

[4] Tsai SJ, Yin MC. Antioxidative and anti-inflammatory protection of oleanolic acid and ursolic acid in PC12 cells[J]. J Food Sci, 2008, 73(7): 174-178.

[5] Zhao HZ, Zhou MJ, Duan LF, et al. Efficient synthesis and anti-fungal activity of oleanolic acid oxime esters[J]. Molecules, 2013, 18(3): 3615-3629.

[6] Tang C, Chen Y, Bai S, et al. Advances in the study of structural modification and biological activities of oleanolic acid[J]. Chin J Org Chem, 2013, 33(1): 46-65.

[7] Luo HQ, Liu JN, Ouyang Q, et al. The effects of oleanolic acid on atherosclerosis in different animal models[J]. Acta Bioch Bioph Sin, 2017, 49(4): 349-354.

[8] Jeong DW, Kim YH, Kim HH, et al. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats[J]. Biopharm Drug Dispos, 2007, 28(2): 51-57.

[9] Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability[J]. Pharm Res, 1995, 12(3): 413-420.

[10] Salvador JAR, Leal AS, Valdeira AS, et al. Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: recent advances in cancer treatment[J]. Eur J Med Chem, 2017, 142: 95-130.

[11] Wang Q, Meng YQ. Synthesis and anti-tumor activity of oleanolic acid a ring derivatives in vitro[J]. J Shenyang Univ Chem Technol, 2020, 34(2): 125-129.

[12] Wei GF, Luan WJ, Wang S, et al. A library of 1,2,3-triazole-substituted oleanolic acid derivatives as anticancer agents: design, synthesis, and biological evaluation[J]. Org Biomol Chem, 2015, 13(5): 1507-1514.

[13] Liu B, Hu GQ, Kang YH. Research progress of the mechanism on antitumor activity of the triazole derivatives[J]. Pharm Biotechnol, 2009, 16(5): 472-476.

[14] Sun KW, Xu YR, Song J, et al. Synthesis and in vitro antitumor activities of oleanolic acid C-28 tetrazole derivatives[J]. J Yantai Univ (Nat Sci Eng Edit), 2021, 34(3): 282-288.

[15] Tirino V, Desiderio V, Paino F, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization[J]. FASEB J, 2013, 27(1): 13-24.

[16] Sang F, Ding Y, Wang JH, et al. Structure-activity relationship study of rakicidins: overcoming chronic myeloid leukemia resistance to imatinib with 4-methylester-rakicidin A[J]. J Med Chem, 2016, 59(3): 1184-1196.

[17] Wang J, Kuang B, Guo X, et al. Total syntheses and biological activities of vinylamycin analogues[J]. J Med Chem, 2017, 60(3): 1189-1209.

[18] Liu S, Gao X, Zhang L, et al. A novel anti-cancer stem cells compound optimized from the natural symplostatin 4 scaffold inhibits Wnt/b-catenin signaling pathway[J]. Eur J Med Chem, 2018, 156: 21-42.

[19] Zhang BY, Zheng YF, Zhao J, et al. Identification of multi-target anti-cancer agents from TCM formula by in silico prediction and in vitro validation[J]. Chin J Nat Med, 2022, 20(5): 332-351.

[20] Liu XH, Li BL, Zhang Z, et al. Synthesis and discovery novel anti-cancer stem cells compounds derived from the natural triterpenoic acids[J]. J Med Chem, 2018, 61(23): 10814-10833.

[21] Liang H, Tong WY, Zhao YY, et al. An antitumor compound julibroside J28 from Albizia julibrissin[J]. Bioorg Med Chem Lett, 2005, 15(20): 4493-4495.

[22] Liu Y, Yang YT, Wang HH, et al. Dammarane-type triterpenoid saponins isolated from Gynostemma pentaphyllum ameliorate liver fibrosis via agonizing PP2Cα and inhibiting deposition of extracellular matrix[J]. Chin J Nat Med, 2023, 21(8): 599-609.

[23] Krief S, Thoison O, Sevenet T, et al. Triterpenoid saponin anthranilates from albiziagrandibracteata leaves ingested by primates in uganda[J]. J Nat Prod, 2005, 68(6): 897-903.

[24] Zou K, Tong WY, Liang H, et al. Diastereoisomeric saponins from Albizia julibrissin[J]. Carbohydr Res, 2005, 340(7): 1329-1334.

[25] Juang YP, Lin YY, Chan SH, et al. Synthesis, distribution analysis and mechanism studies of N-acyl glucosamine-bearing oleanolic saponins[J]. Bioorg Chem, 2020, 99: 103835.

[26] Wang P, Wang J, Guo TT, et al. Synthesis and cytotoxic activity of the N-acetylglucosamine-bearing triterpenoid saponins[J]. Carbohydr Res, 2010, 345(5): 607-620.

[27] Wang B, Liu Y, Wang YS, et al. Syntheses and structure-activity relationship studies of N-substituted-β-D-glucosaminides as selective cytotoxic agents[J]. Bioorg Med Chem Lett, 2012, 22(23): 7110-7113.

[28] Ren L, Liu Y, Yu GH, et al. Synthesis and tumor cytotoxicity of novel N-substituted glucosamine bearing oleanolic acid derivatives[J]. Chem Res Chin Univ, 2014, 30(4): 639-643.

[29] Liu QC, Liu HC, Zhang L, et al. Synthesis and antitumor activities of naturally occurring oleanolic acid triterpenoid saponins and their derivatives[J]. Eur J Med Chem, 2013, 64: 1-15.

[30] Sun JS, Han XW, Yu B. Synthesis of a typical N-acetylglucosamine-containing saponin, oleanolic acid 3-yl-α-L-arabinopyranosyl-(1-2)-α-L-arabinopyranosyl-(1-6)-2-acetamido-2-deoxy-β-D-glucopyranoside[J]. Carbohyd Res, 2003, 338(9): 827-833.

[31] Abdel-Kader M, Hoch J, Berger JM. Two bioactive saponins from Albizia subdimidiata from the suriname rainforest[J]. J Nat Prod, 2001, 64(4): 536-539.

[32] Seo Y, Hoch J, Abdel-Kader M, et al. Bioactive saponins from Acacia tenuifolia from the suriname rainforest[J]. J Nat Prod, 2002, 65(2): 170-174.

[33] Yan MC, Liu Y, Chen H, et al. Synthesis and antitumor activity of two natural N-acetylglucosamine-bearing triterpenoid saponins: lotoidoside D and E[J]. Bioorg Med Chem Lett, 2006, 16(16): 4200-4204.

[34] Lin YY, Chan SH, Juang YP, et al. Design, synthesis and cytotoxic activity of N-Modified oleanolic saponins bearing A glucosamine[J]. Eur J Med Chem, 2018, 143: 1942-1958.

[35] Medina-O’ Donnell M, Rivas F, Reyes-Zurita FJ, et al. Diamine and PEGylated-diamine conjugates of triterpenic acids as potential anticancer agents[J]. Eur J Med Chem, 2018, 148: 325-336.

[36] Monteiro HP, Costa PE, Reis AK, et al. Nitric oxide: protein tyrosine phosphorylation and protein S-nitrosylation in cancer[J]. Biomed J, 2015, 38: 380-388.

[37] Chen Z, Huang KY, Ling Y, et al. Discovery of an oleanolic acid/hederagenin-nitric oxide donor hybrid as an EGFR tyrosine kinase inhibitor for non-small-cell lung cancer[J]. J Nat Prod, 2019, 82(11): 3065-3073.

[38] Serafim RAM, Primi MC, Trossini GHG, et al. Nitric oxide: state of the art in drug design[J]. Curr Med Chem, 2012, 19(3): 386-405.

[39] Chen L, Zhang YH, Kong XW, et al. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid[J]. J Med Chem, 2008, 51(15): 4834-4838.

[40] Fu JJ, Liu L, Huang ZJ, et al. Hybrid molecule from O₂-(2,4-dinitrophenyl) diazeniumdiolate and oleanolic acid: a glutathione S-transferase pi-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability[J]. J Med Chem, 2013, 56(11): 4641-4655.

[41] Fu JJ Zou, ZY, Huang ZJ, et al. Identification of nitric oxide-releasing derivatives of oleanolic acid as potential anti-colon cancer agents[J]. RSC Adv, 2015, 5(25): 19445-19454.

[42] Ai Y, Kang FH, Huang ZJ, et al. Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer[J]. J Med Chem, 2015, 58(5): 2452-2464.

[43] Zou Y, Yan C, Liu JC, et al. Synthesis and anti-hepatocellular carcinoma activity of novel O²-vinyl diazeniumdiolate-based nitric oxide-releasing derivatives of oleanolic acid[J]. Chin J Nat Med, 2017, 15(12): 928-937.

[44] Smith RAJ, Hartley RC, Cocheme HM, et al. Mitochondrial pharmacology[J]. Trends Pharmacol Sci, 2012, 33(6): 341-352.

[45] Nunnari J, Suomalainen A. Mitochondria: in sickness and in health[J]. Cell, 2012, 148(6): 1145-1159.

[46] Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them[J]. Trends Cell Biol, 2008, 18(4): 165-173.

[47] Miettinen K, Pollier J, Buyst D, et al. The ancient CYP716 family is a major contributor to the diversification of eudicot triterpenoid biosynthesis[J]. Nat Commun, 2017, 8: 14153.

[48] Hu S, Wang Z, Hou T. Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists[J]. Bioorg Med Chem, 2015, 23(5): 1157-1168.

[49] Lei M, Xiao Z, Ma B, et al. Synthesis and biological evaluation of bufalin-3-yl nitrogen-containing-carbamate derivatives as anticancer agents[J]. Steroids, 2016, 108: 56-60.

[50] Teimoori S, Panjamurthy K, Vinaya K, et al. Synthesis and antiproliferative activity of novel homopiperazine derivatives in leukemia cells[J]. Chem Biol Interface, 2011, 1: 59-67.

[51] Vanden EJJ, Mayence A, Johnson MT, et al. Antitumor and anti-pneumocystis carinii activities of novel bisbenzamidines[J]. Med Chem Res, 2005, 14: 143-157.

[52] Wang N, Switalska M, Wu MY, et al. Synthesis and in vitro cytotoxic effect of 6-amino-substituted 11H- and 11Me-indolo[3,2-c] quinolines[J]. Eur J Med Chem, 2014, 78(6): 314-323.

[53] Wolfram RK, Fischer L, Kluge R, et al. Homopiperazine-rhodamine B adducts of triterpenoic acids are strong mitocans[J]. Eur J Med Chem, 2018, 155: 869-879.

[54] De P, Baltas M, Bedos-Belval F. Cinnamic acid derivatives as anticancer agents-a review[J]. Curr Med Chem, 2011, 18(11): 1672-1703.

[55] Hunke M, Martinez W, Kashyap A, et al. Antineoplastic actions of cinnamic acids and their dimers in breast cancer cells: a comparative study[J]. Anticancer Res, 2018, 38(8): 4469-4474.

[56] Su P, Shi YL, Wang JF, et al. Anticancer agents derived from natural cinnamic acids[J]. Anticancer Agents Med Chem, 2015, 15(8): 980-987.

[57] Wang R, Yang W, Fan Y, et al. Design and synthesis of the novel oleanolic acid-cinnamic acid ester derivatives and glycyrrhetinic acid-cinnamic acid ester derivatives with cytotoxic properties[J]. Bioorg Chem, 2019, 88: 102951.

[58] Liu CM, Huang JY, Sheng LX, et al. Synthesis and antitumor activity of fluorouracil: oleanolic acid/ursolic acid/glycyrrhetinic acid conjugates[J]. Med Chem Commun, 2019, 10(8): 1370-1378.

[59] Yu M, Si LL, Wang YF, et al. Discovery of pentacyclic triterpenoids as potential entry inhibitors of influenza viruses[J]. J Med Chem, 2014, 57(23): 10058-10071.

[60] Su YQ, Meng LK, Sun JQ, et al. Design, synthesis of oleanolic acid-saccharide conjugates using click chemistry methodology and study of their anti-influenza activity[J]. Eur J Med Chem, 2019, 182: 111622.

[61] Li SM, Jia XH, Shen XT, et al. Structure-activity relationships of 3-O-β-chacotriosyl oleanic acid derivatives as entry inhibitors for highly pathogenic H5N1 influenza virus[J]. Bioorg Med Chem, 2017, 25(16): 4384-4396.

[62] Song GP, Shen XT, Li SM, et al. Structure-activity relationships of 3-O-β-chacotriosyl oleanane-type triterpenoids as potential H5N1 entry inhibitors[J]. Eur J Med Chem, 2016, 119: 109-121.

[63] Song GP, Shen XT, Li SM, et al. Discovery of 3-O-β-chacotriosyl oleanane-type triterpenes as H5N1 entry inhibitors[J]. RSC Adv, 2015, 5(49): 39145-39154.

[64] Yu F, Wang Q, Zhang Z, et al. Development of oleanane-type triterpenes as a new class of HCV entry inhibitors[J]. J Med Chem, 2013, 56(11): 4300-4319.

[65] Yang Y, He HJ, Chang H, et al. Multivalent oleanolic acid human serum albumin conjugate as nonglycosylated neomucin for influenza virus capture and entry inhibition[J]. Eur J Med Chem, 2018, 143: 1723-1731.

[66] Medina-O’Donnell M, Rivas F, Reyes-Zurita FJ, et al. Oleanolic acid derivatives as potential inhibitors of HIV-1 protease[J]. J Nat Prod, 2019, 82(10): 2886-2896.

[67] Li HW, Li M, Xu RY, et al. Synthesis, structure activity relationship and in vitro anti-influenza virus activity of novel polyphenol-pentacyclic triterpene conjugates[J]. Eur J Med Chem, 2019, 163: 560-568.

[68] Meng LK, Su YQ, Yang F, et al. Design, synthesis and biological evaluation of amino acids-oleanolic acid conjugates as influenza virus inhibitors[J]. Bioorg Med Chem, 2019, 27(23): 115147.

[69] Zhong YY, Chen HS, Wu PP, et al. Synthesis and biological evaluation of novel oleanolic acid analogues as potential α-glucosidase inhibitors[J]. Eur J Med Chem, 2019, 164: 706-716.

[70] Qian S, Li HJ, Chen Y, et al. Synthesis and biological evaluation of oleanolic acid derivatives as inhibitors of protein tyrosine phosphatase 1B[J]. J Nat Prod, 2010, 73(11): 1743-1750.

[71] Liu QC, Guo TT, Zhang L, et al. Synthesis and biological evaluation of oleanolic acid derivatives as PTP1B inhibitors[J]. Eur J Med Chem, 2013, 63: 511-522.

[72] Ramírez-Espinosa JJ, Rios MY, Paoli P, et al. Synthesis of oleanolic acid derivatives: in vitro, in vivo and in silico studies for PTP-1B inhibition[J]. Eur J Med Chem, 2014, 87: 316-327.

[73] Chang YZ, Zhou SX, Li EQ, et al. Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors[J]. Eur J Med Chem, 2017, 126: 143-153.

[74] Braca A, Dal PF, Marzocco S, et al. Triterpene derivatives as inhibitors of protein involved in the inflammatory process: molecules interfering with phospholipase A2, cycloxygenase, and lipoxygenase[J]. Curr Drug Targets, 2011, 12(3): 302-321.

[75] Chan KY, Mohamad K, Ooi AJ, et al. Bioactivity-guided fractionation of the lipoxygenase and cyclooxygenase inhibiting constituents from Chisocheton polyandrus Merr[J]. Fitoterapia, 2012, 83(5): 961-967.

[76] Chung LY, Soo WK, Chan KY, et al. Imiyabir, lipoxygenase inhibiting activity of some Malaysian plants[J]. Pharm Biol, 2009, 47(12): 1142-1148.

[77] Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs[J]. Ann Rheum Dis, 2003, 62(6): 501-509.

[78] Chen XC, Ly Y, Liu Y, et al. Identification of a cytochrome P450 from Tripterygium hypoglaucum (Levl.) Hutch that catalyzes polpunonic acid formation in celastrol biosynthesis[J]. Chin J Nat Med, 2022, 20(9): 691-700.

[79] Vo NNQ, Nomura Y, Muranaka T, et al. Structure-activity relationships of pentacyclic triterpenoids as inhibitors of cyclooxygenase and lipoxygenase enzymes[J]. J Nat Prod, 2019, 82(12): 3311-3320.

[80] Hardie DG, Schaffer BE, Brunt A. AMPK: an energy-sensing pathway with multiple inputs and outputs[J]. Trends Cell Biol, 2016, 26(3): 190-201.

[81] Antonioli L, Colucci R, Pellegrini C, et al. The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders[J]. Expert Opin Ther Targets, 2016, 20(2): 179-191.

[82] Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs[J]. J Biol Chem, 2004, 279(20): 20767-20774.

[83] Nath N, Giri S, Prasad R, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis[J]. J Immunol, 2005, 175(1): 566-574.

[84] Prasad R, Giri S, Nath N, et al. 5-Aminoimidazole-4-carboxamide-L-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction[J]. J Neurosci Res, 2006, 84(3): 614-625.

[85] Nath N, Khan M, Paintlia MK, et al. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis[J]. J Immunol, 2009, 182(12): 8005-8014.

[86] Myerburg MM, King JD, Jr Oyster NM, et al. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells[J]. Am J Respir Cell Mol Biol, 2010, 42(6): 676-684.

[87] Wang JY, Ma H, Zhang XY, et al. A novel AMPK activator from Chinese herb medicine and ischemia phosphorylate the cardiac transcription factor FOXO3[J]. Int J Physiol Pathophysiol Pharmacol, 2009, 1(2): 116-126.

[88] Wang X, Liu R, Zhang W, et al. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects[J]. Mol Cell Endocrinol, 2013, 376(1-2): 70-80.

[89] Liu J, Zheng LH, Wu N, et al. Oleanolic acid induces metabolic adaptation in cancer cells by activating the AMP-activated protein kinase pathway[J]. J Agric Food Chem, 2014, 62(24): 5528-5537.

[90] Nie H, Wang Y, Qin Y, et al. Oleanolic acid induces autophagic death in human gastric cancer cells in vitro and in vivo[J]. Cell Biol Int, 2016, 40(7): 770-778.

[91] Liu L, Li HB, Hu KW, et al. Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid[J]. Eur J Med Chem, 2021, 209: 112932.

[92] Bhandari P, Patel NK, Gangwal RP, et al. Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies[J]. Bioorg Med Chem Lett, 2014, 24(17): 4114-4119.

[93] Jannus F, Medina-O’Donnell M, Neubrand VE, et al. Efficient in vitro and in vivo anti-inflammatory activity of a diamine-PEGylated oleanolic acid derivative[J]. Int J Mol Sci, 2021, 22(15): 8158.

[94] Yu ZJ, Sun WZ, Peng WB, et al. Pharmacokinetics in vitro and in vivo of two novel prodrugs of oleanolic acid in rats and its hepatoprotective effects against liver injury induced by CCl₄[J]. Mol Pharm, 2016, 13(5): 1699-1710.

[95] Saczewski F, Balewski Ł. Biological activities of guanidine compounds[J]. Expert Opin Ther Pat, 2009, 19(10): 1417-1448.

[96] Castagnolo D, Schenone S, Botta M. Guanylated diamines, triamines, and polyamines: chemistry and biological properties[J]. Chem Rev, 2011, 111(9): 5247-5300.

[97] Wexselblatt E, Esko JD, Tor Y. On guanidinium and cellular uptake[J]. J Org Chem, 2014, 79(15): 6766-6774.

[98] Yu SA, Khalitova RR, Nedopekina DA, et al. Antimicrobial properties of amine- and guanidine-functionalized derivatives of betulinic, ursolic and oleanolic acids: synthesis and structure/activity evaluation[J]. Steroids, 2020, 154: 108530.

[99] Blanco-Cabra N, Vega-Granados K, Moya-Andérico L, et al. Novel oleanolic and maslinic acids derivatives as a promising treatment against bacterial biofilm in nosocomial infections: an in vitro and in vivo study[J]. ACS Infect Dis, 2019, 5(9): 1581-1589.

[100] Zhou YL, Guo Y, Sun XD, et al. Application of oleanolic acid and its analogues in combating pathogenic bacteria in vitro/vivo by a two-pronged strategy of β-lactamases and hemolysins[J]. ACS Omega, 2020, 5(20): 11424-11438.

[101] Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of alzheimer type[J]. Neuropathol Appl Neurobiol, 1978, 4(4): 273-277.

[102] Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer-disease-evidence for selective loss of cholinergic neurons in the nucleus basalis[J]. Ann Neurol, 1981, 10(2): 122-126.

[103] Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction[J]. Science, 1982, 217(4558): 408-414.

[104] Coyle JT, Price DL, Delong MR. Alzheimers-disease a disorder of cortical cholinergic innervation[J]. Science, 1983, 219(4589): 1184-1190.

[105] Harrell LE. Cholinesterases and cholinesterase inhibitors[J]. Arch Neurol, 2001, 58(3): 516.

[106] Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine[J]. Neuroscience, 2002, 110(4): 627-639.

[107] Loesche A, Köwitsch A, Lucas SD, et al. Ursolic and oleanolic acid derivatives with cholinesterase inhibiting potential[J]. Bioorg Chem, 2019, 85: 23-32.

[108] JS Seo, TK Kim, YH Leem, et al. SK-PC-B70M confers anti-oxidant activity and reduces Ab levels in the brain of Tg2576 mice[J]. Brain Res, 2009, 1261: 100-108.

[109] Gülçin I, Mshvildadze V, Gepdiremen A, et al. Antioxidant activity of saponins isolated from ivy: alpha-hederin, hederasaponin-C, hederacolchiside-E and hederacolchiside-F[J]. Planta Med, 2004, 70(6): 561-563.

[110] Li HN, Liu Y, Zhang ZP, et al. Synthesis, biological evaluation and structure-activity relationship studies of hederacolchiside E and its derivatives as potential anti-Alzheimer agents[J]. Eur J Med Chem, 2018, 143: 376-389.

[111] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years[J]. EMBO Mol Med, 2016, 8(6): 595-608.

[112] Luo WJ, Ip FCF, Fu GM, et al. A pentacyclic triterpene from Ligustrum lucidum targets γ-secretase[J]. ACS Chem Neurosci, 2020, 11(18): 2827-2835.

Funding

Lianyungang Postdoctoral Research Funding Program(LYG20210018)